A $5 million prize awaits proof that quantum computers can solve health care problems - MIT Technology Review
Infleqtion wants to put its quantum computer in your car. The Colorado-based company has built a cesium atom system compact enough to theoretically cart around, though its actual capabilities will be tested starting March 24 at an event in Marina del Rey, California. The occasion is the $5 million Q4Bio prize, run by the nonprofit Wellcome Leap. Win conditions: $2 million for any team running a useful health algorithm on 50 or more qubits, $5 million grand prize for solving a significant real-world health problem with 100 or more qubits that no classical computer can touch.
This is the stress test quantum computing has been building toward. Not a victory lap.
Twelve teams entered Q4Bio in 2024, each receiving $1.5 million in funding. Six reached the finalist stage. What they all have in common, beneath the surface differences, is that none of them are running a pure quantum system. Every finalist uses a quantum-classical hybrid. The quantum processor handles the specific subroutines where classical methods stop scaling; classical algorithms do everything else. This is the honest version of where quantum computing actually is in 2026, and Q4Bio is forcing teams to be explicit about it.
The approaches are genuinely varied. A team led by Sergii Strelchuk at Oxford University is using quantum hardware to map genetic diversity among humans and pathogens on graph-based structures, looking for hidden connections in treatment pathways. The classical tools for this kind of analysis struggle even at moderate scale; the quantum processor is brought in selectively. Algorithmiq, based in Helsinki, has used IBM's superconducting quantum computer to simulate a cancer drug activated by specific wavelengths of light. The drug is already in Phase II clinical trials for bladder cancer. The quantum simulation, which improves on classical algorithms, is aimed at redesigning it for other conditions. The company's CEO, Sabrina Maniscalco, describes the methods as applicable across healthcare simulation broadly. The short version: a drug that currently works in one context because it can't be fully simulated classically might be expanded to work in others, once the simulation bottleneck is removed.
Infleqtion's entry uses its cesium atom machine to find patterns in the Cancer Genome Atlas, massive data sets that overwhelm classical solvers. The quantum processor identifies correlations that reduce the problem size; the classical solver takes over from there. Teague Tomesh, Infleqtion's Q4Bio project lead, describes the goal as using the best of both resources.
The Nottingham team is working on a drug candidate for myotonic dystrophy, the most common adult-onset form of muscular dystrophy. One team member, David Brook, helped identify the gene responsible in 1992. Thirty years later, the group is using QuEra's neutral atom quantum computer in Boston to compute drug-protein binding configurations that might block the disease mechanism. This is a long-horizon result: the target is clear, the quantum-computed path to it is new.
Program director Shihan Sajeed is less confident than the teams. He believes the grand prize criteria are set above what current error-prone machines can reliably deliver. The combination of 100-plus qubits, demonstrated error correction, and a health problem provably outside classical reach is a high bar. His estimate: much of the prize money could stay in Wellcome Leap's account.
The Q4Bio finalists were selected from 133 submissions across 31 countries. Seven teams now share $1 million, with $4 million remaining including a $3 million grand prize, to be awarded in March 2027. Teams not selected may re-enter through a wildcard round that opened January 14 and closes March 4, 2026.
Ryan Babbush, Director of Research for Quantum Algorithms and Applications at Google Quantum AI, frames the competition as a diagnostic tool embedded in a five-stage framework for quantum application development. Stage II involves finding concrete, verifiable problems where quantum outperforms the best classical methods on real instances. Stage III connects mathematically demonstrated advantage to specific industrial use cases in pharmaceuticals or materials science. Q4Bio is deliberately testing the gap between Stage II and Stage III.
Google's own recent work is relevant context. The Willow chip demonstrated error correction improvements. The Quantum Echoes algorithm, also on Willow, produced what Google calls the first demonstration of verifiable quantum advantage, meaning the output of a quantum circuit can be checked by a classical computer in a way that rules out classical simulation. Neither of these results is part of Q4Bio, but they define the environment in which the competition operates.
The honest answer about quantum computing in 2026 is that it exists in a narrow band: useful for specific subroutines within larger classical workflows, not yet as a standalone problem-solver at scale. Q4Bio is designed to map that band precisely. Whether any team crosses the threshold in Marina del Rey this month remains an open question. Sajeed's skepticism is shared by people who watch this field closely. The prize structure is set up to reward progress, not to guarantee it. That distinction matters more than the money.